BMEABiomea Fusion, Inc.

Nasdaq biomeafusion.com


$ 5.64 $ -0.17 (-2.93 %)    

Friday, 14-Jun-2024 15:59:49 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 5.64
$ 5.62
$ 0.00 x 0
$ 0.00 x 0
$ 5.58 - $ 6.09
$ 3.61 - $ 38.84
2,267,888
na
202.42M
$ 0.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 10-30-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-27-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-downgrades-biomea-fusion-to-hold

Truist Securities analyst Robyn Karnauskas downgrades Biomea Fusion (NASDAQ:BMEA) from Buy to Hold.

 citigroup-maintains-buy-on-biomea-fusion-lowers-price-target-to-45

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $90 to...

 hc-wainwright--co-maintains-buy-on-biomea-fusion-lowers-price-target-to-15

HC Wainwright & Co. analyst Joseph Pantginis maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price targe...

 why-biomea-fusion-bmea-stock-is-down-60

Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its ...

 piper-sandler-maintains-overweight-on-biomea-fusion-lowers-price-target-to-10

Piper Sandler analyst Joseph Catanzaro maintains Biomea Fusion (NASDAQ:BMEA) with a Overweight and lowers the price target f...

 barclays-downgrades-biomea-fusion-to-equal-weight-lowers-price-target-to-5

Barclays analyst Peter Lawson downgrades Biomea Fusion (NASDAQ:BMEA) from Overweight to Equal-Weight and lowers the price ta...

 scotiabank-maintains-sector-outperform-on-biomea-fusion-lowers-price-target-to-21

Scotiabank analyst George Farmer maintains Biomea Fusion (NASDAQ:BMEA) with a Sector Outperform and lowers the price target ...

 this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials

Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported.